Navigation Links
Arcion Therapeutics' Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
Date:7/20/2010

low or undetectable.  No serious or severe adverse events were attributable to ARC-4558 treatment and the topical formulation was well-tolerated at the site of skin application.  

"The top-line data reported today for ARC-4558 provide strong support for Arcion's fundamental approach of applying therapies topically to relieve neuropathic pain by targeting nerve signaling at the level of the skin," said James Campbell, M.D., President and CEO of Arcion. "Through this study, we identified a simple, predictive clinical test to identify non-responders to ARC-4558, which should enable us to optimize subject enrollment in future studies.  Based on our successful End of Phase 2 meeting with the FDA, we believe ARC-4558 will be the first PDN treatment indicated to treat patients who have demonstrable functional nociceptors in the skin.  The full Phase 2b results will be submitted for future peer review and we look forward to advancing the ARC-4558 program in Phase 3 studies."

Michael C. Rowbotham, M.D., Adjunct Professor of Neurology and Anesthesia and Director, UCSF Pain Clinical Research Center, commented, "Painful diabetic neuropathy is frequently a debilitating condition that severely impacts a patient's quality of life and ability to carry out normal day-to-day functions.  There are approved therapies to control the pain, but issues of tolerability and efficacy seriously limit their usefulness.  A novel mechanism-based topical treatment with a low liability of systemic side effects has promise to advance significantly the treatment of this condition and improve the quality of life for a large number of patients."

About the Phase 2b Trial

The Phase 2b study included an adaptive trial design and enrolled a total of 180 adult patients with PDN. Pati
'/>"/>

SOURCE Arcion Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anesiva Announces Merger With Arcion Therapeutics Will Not be Completed
2. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
3. Elusys Therapeutics and Lonza Extend Manufacturing Agreement for Anthim, a New Anthrax Treatment in Late-Stage Development
4. Silence Therapeutics and AstraZeneca Extend siRNA Development Collaboration
5. Nile Therapeutics Completes Dosing of Phase II Study
6. Cornerstone Therapeutics Announces Management Change
7. Nonconformity of NOV002 Used in Phase 3 NSCLC Trial Sponsored by Novelos Therapeutics, Inc to NOV002 (Glutoxim(R)), Used in Phase 1/2 NSCLC and all Previous Trials
8. InteKrin Therapeutics Presented Phase 2b Clinical Data at the 2010 American Diabetes Association Annual Meeting, Demonstrating Improved Glycemic Control in Patients with Type 2 Diabetes Without Causing the Edema Seen with Pioglitazone
9. Global Melanoma Therapeutics Industry
10. Tolera Therapeutics Granted Orphan Drug Designation for Treatment of Type 1 diabetes mellitus
11. TransGenRx Protein Therapeutics Technology to Support Research Related to Protein-Based HDL Therapies at Esperion Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and NEW PROVIDENCE, N.J. , July ... are invited to meet with Linde,s Healthcare division ... to be held at McCormick Place in ... "Hospitals demand nothing less than complete confidence in ... , Linde,s Healthcare Segment manager. "Linde understands the importance ...
(Date:7/28/2014)... INCLINE VILLAGE, Nev. , July 28, 2014 ... announced that the Company will release its second quarter 2014 ... Monday, August 11, 2014, after market close. PDL,s management will ... p.m. Eastern Time to discuss the financial results.  A slide ... webcast link on the PDL website. Conference Call ...
(Date:7/28/2014)... , July 28, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... Second Quarter 2014 Financial Results and Highlights Conference CallWhen:Monday, ... PTWhere: www.isispharm.com How:Live on the Internet. Simply log ... to participate during the live event, a replay of ... at www.isispharm.com . ABOUT ISIS PHARMACEUTICALS, ...
Breaking Medicine Technology:Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2PDL BioPharma to Announce Second Quarter 2014 Financial Results on August 11, 2014 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... 17, 2011 Reportlinker.com announces that a ... its catalogue: Depression Therapeutics ... 2018 http://www.reportlinker.com/p0656880/Depression-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2018.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... and Market Forecasts to 2018 ...
... Par Pharmaceutical, Inc., the wholly-owned subsidiary of Par ... announced that it filed a declaratory judgment complaint and ... in Washington, D.C. seeking to preserve Par,s First Amendment ... healthcare providers about the FDA-approved, on-label use of Par,s ...
Cached Medicine Technology:Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 2Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 3Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 4Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 5Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 6Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 7Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 8Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 9Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2018 10Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 2Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 3Par Pharmaceutical Files Declaratory Judgment to Protect First Amendment Rights to Disseminate Truthful Information Regarding Megace® ES 4
(Date:7/28/2014)... 2014 This is a professional ... Tadalafil industry. The report firstly reviews the basic ... manufacturing technology. The report then explores global and ... specification, capacity, Production value, and market share etc. ... and China’s total market of Tadalafil by calculation ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Mahendra Trivedi, ... hosted the Trivedi Online Workshop ‘Consciousness is Power’ on ... (EST). During this workshop, participants from all over the ... of making a deeper connection to their inner guidance ... participants explored the various advantages of raising consciousness and ...
(Date:7/28/2014)... 2014 Scientists in Japan have completed ... blood test for the asbestos cancer mesothelioma. Surviving Mesothelioma ... Click here to read it now. , ... Juntendo University Graduate School of Medicine say a new ... step above the old test. , “Particularly for ...
(Date:7/28/2014)... Wisconsin (PRWEB) July 28, 2014 ... business process outsourcing (BPO) for Fortune 500 brands, announced ... jobs across its locations in Wisconsin, California, Florida and ... be based at its Neenah campus. , A majority ... which have seasonal ramp-ups that require additional staffing in ...
(Date:7/28/2014)... Community Health Center of Snohomish County (CHC), ... services, has released an article designed to educate patients ... Founded in 1983, the health center has a strong ... that face barriers to obtaining high quality yet affordable ... the CHC, click here: http://www.chcsno.org/locations.ashx?p=1099 , The ...
Breaking Medicine News(10 mins):Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Global and Chinese Tadalafil Industry 2009-2019 Market Research Report Now Available at LifeScienceIndustryResearch.com 4Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Test Results Look Promising for New Mesothelioma Blood Test, According to Surviving Mesothelioma 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 2Health News:Alta Resources To Fill Approximately 600 Positions In Neenah 3Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 2Health News:Community Health Center of Snohomish Releases Article Focusing on Educating the Chronically Ill About Chronic Disease Management 3
... 30 years of HIV on an area once described as ... at a lecture hosted by the University of East Anglia ... production, with dire consequences for rural livelihoods, were originally predicted ... AIDS in central and south western Uganda. However, recent research ...
... , THURSDAY, Nov. 11 (HealthDay News) -- Researchers have pinpointed ... (AKI), a finding they believe could lead to a simple ... AKI usually doesn,t show obvious physical symptoms, which is ... The study found that urine samples from mice and ...
... 11, 2010 A new study from researchers in Colorado ... likely to undergo a screening colonoscopy than those who were ... female endoscopists seem to be common among women. In this ... that rates of screening colonoscopy can be increased by offering ...
... THURSDAY, Nov. 12 (HealthDay News) -- If you want to be ... people,s minds drifted from the task or activity at hand, they ... whatever they were doing. The human mind is uniquely capable ... to anticipate things that will happen, and to plan for things ...
... Gardner HealthDay Reporter , THURSDAY, Nov. 11 (HealthDay ... plans will come across some changes as they choose a ... open enrollment period, but experts say those differences won,t be ... Dec. 31, and any changes will take effect Jan. 1, ...
... "This ESMO-symposium will allow bed-side oriented oncologists to ... All presentations will have a clear focus towards ... the major consequences that new developments in cancer ... Soria, Symposium Co-Chair The ESMO Symposium on ...
Cached Medicine News:Health News:30 years on in the epicenter of the African AIDS epidemic 2Health News:Urine Markers May Reveal Kidney Damage Earlier 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 2Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 3Health News:Screening colonoscopy rates are not increased when women are offered a female endoscopist 4Health News:Happiness Is a Focused Mind 2Health News:Happiness Is a Focused Mind 3Health News:Medicare Part D Changes Not Overwhelming, Experts Say 2Health News:Medicare Part D Changes Not Overwhelming, Experts Say 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: